conferenceseries.com

13th European Biosimilars Congress

April 01-02, 2020
London, UK



SCIENTIFIC PROGRAM

DAY 1
Wednesday 01st, April

08:30-09:00 **Registrations**

09:00-09:30 **Introduction**

09:30-09:50 COFFEE BREAK

09:50-11:50 Meeting Hall 01 **KEYNOTE LECTURES**

11:50-13:10

MEETING HALL 01	MEETING HALL 02
Talks On: Current Challenges in Developing Biosimilars	**Talks On: Analytical Strategies for Biosimilars and Intellectual Property Rights**
Biopharmaceuticals development	Biosimilars multimodal techniques
Quality by Design for Biologics and Biosimilars	Biosimilars bioanalytical methods
Implimentation of the BPCI Act	Bioassay for comparability and potency testing
Advertising, promotion and labelling essentials	Biosimilars LC/MS analysis for discovery, preclinical and clinical programs
Unique considerations for biologics	Biosimilars GMP protein analysis
Comparability for biologics	Biosimilars electrophoresis

13:10-13:15 GROUP PHOTO

13:15-14:00 LUNCH BREAK

14:00-16:00

MEETING HALL 01	MEETING HALL 02
Talks On: Biological Medicine and Emerging Biosimilars in Therapeutics	**Talks On: Innovative Clinical Approach in Biosimilars and Biosimilars Research Pipeline**
Advances in biological products	Biosimilars clinical trials
Biological drugs	Clinical PK/PD studies
Generic biological drugs	Toxicological studies
Biologics in cancer	Risk management and quality affairs
Biologics in autoimmune disease	Future of next generation biosimilars

16:00-16:20 COFFEE BREAK

MEETING HALL 01 (16:20-17:00)	MEETING HALL 01 (17:00-18:00)
Young Researchers in Pharmaceutical Sciences	**Workshop**

DAY 2
Thursday 02nd, April

09:00-10:30 Meeting Hall 01 — **KEYNOTE LECTURES**

10:30-10:50 COFFEE BREAK

10:50-12:50	MEETING HALL 01	MEETING HALL 02
	Talks On: Regulatory Updates on Biosimilars & Biosimilars Development in Markets	**Talks On:** Biosimilars Approval to Biogenerics in Clinical Practice
	Licensing of biosimilars	Biotechnologic drug
	BLA filing for biosimilars	Monoclonal antibody
	Regulatory prospects of BRIC countries	Fusion protein
	Biosimilars USA	Biologic drug
	Biosimilars Europe	Anti–tumor necrosis factor

12:50-13:35 LUNCH BREAK

13:35-15:55	MEETING HALL 01	MEETING HALL 02
	Talks On: Biopharmaceutical Informatics & Consequences of Brexit on Biosimilars	**Talks On:** BCS and IVIVC Based Biowaivers & Globalization of Biosimilars
	Applications of computation in biologic drug development	BCS biowaivers
	Physics-based molecular modelling	Preclinical and clinical testing for oral drug delivery
	Protein sequence-structural contexts and degradation reaction mechanisms	Waiver for In vivo bioavailability or bioequivalence
	Brexit- Pros and Cons to European pharma market	Global impact of biosimilars over generics
	Post Brexit changes in biosimilars regulation in UK	Economic aspect towards biosimilars
	Fate of biosimilars clinical trials in UK	Biosimilars in global market

15:55-16:15 COFFEE BREAK

MEETING HALL 01 (16:15-17:00)	MEETING HALL 01 (17:00-18:00)
Poster Presentations	**Workshop**

Organizing Committee Members



Andras Guttman

Sciex Separations, USA



Cecil Nick

PAREXEL, UK



Christoph Volpers

Michalski Hüttermann & Partners, Germany



David Ebsworth

Vifor Pharma Ltd, Switzerland



Dominic Seitz

Simon-Kucher & Partners, Germany



Fiona M Greer

SGS Life Sciences, Switzerland



Francois-Xavier Frapaise

Biosimilars Consultant, France



Kamali Chance

BioSciencesCorp, USA



Parastoo Azadi

Complex Carbohydrtae Research Center - University of Georgia, USA

PAST AFFILIATES

PAST AFFILIATES

Andras Guttman
Sciex Separations, USA

Fiona M Greer
SGS Life Sciences, Switzerland

Francois-Xavier Frapaise
Biosimilars Consultant, France

Parastoo Azadi
Complex Carbohydrtae Research Center - University of Georgia, USA

Cecil Nick
PAREXEL International, UK

Dominic Seitz
Simon-Kucher & Partners, Germany

David Ebsworth
Vifor Pharma Ltd, Switzerland

Sakae Tsuda
National Institute of Advanced Industrial Science and Technology, Japan

Emile Van Corven
Bioceros, Netherlands

Thomas Kofoed
Alphalyse A/S, Denmark

R Helena Bustos-Cruz
Universidad de La Sabana, Colombia

M. Carme Parés Santilari
European Bio Immune(G)ene Medicine Association, France

Kurt R Karst
Hyman, Phelps & McNamara, P C, USA

Kamali Chance
BioSciencesCorp, USA

Roberto Valenti
DLA Piper, Italy

Theo Christie
National Institute for Health Research, UK

Archana Shubhakar
Ludger Ltd, UK

Fatemeh Torkashvand
Pasteur Institute of Iran, Iran

Roberta Bursi
InsilicoTRIALS, Italy

Victor Tsetlin
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Russia

Padma Priya Anand Baskaran
ReeLabs Pvt. Ltd., India

Eraldo Martins Guerra Filho
Recife Center for Advanced Studies and Systems, Brazil

Oleksandr Kukharchuk
ReeLabs Pvt. Ltd., India

Tsachi Shaked
Elcam Drug Delivery Devices, Israel

Menachem Zucker
E3D Elcam Drug Delivery Devices, Israel

Mohammed H Alwan
Al Nahrain University, Iraq

PAST AFFILIATES

PAST AFFILIATES

Logean Q Al Karam
Al Nahrain University, Iraq

Thomas Zahel
Exputec GmbH, Austria

Yazan Shaban
Hikma Pharmaceuticals, Jordan

Cecil Nick
PAREXEL International, UK

Pavel Vítámvás
Crop Research Institute, Czech Republic

Anna Shaliutina-Kolesova
University of South Bohemia Ceské Budejovice, Czech Republic

Hamdi Uysal
Ankara University, Turkey

Hana Ujcikova
Institute of Physiology-Czech Academy of Sciences, Czech Republic

Peter Nilsson
KTH-Royal Institute of Technology, Sweden

Peter Nilsson
KTH-Royal Institute of Technology, Sweden

Sara Motta
National Research Council, Italy

Patrícia Sampaio Tavares Veras
Gonçalo Moniz Research Center- FIOCRUZ, Brazil

Patricia Renard
University of Namur, Belgium

Alex Bayes
Biomedical Research Institute Sant Pau, Spain

Mario Looso
Max Planck Institute for Heart and Lung Research, Germany

Nadine Bongaerts
Delft University of Technology, Netherlands

Lydia Siragusa
Molecular Discovery Limited, UK

Thomas Schneider
Philip Morris International, Switzerland

Miguel Quintela-Fandino
Spanish National Cancer Research Center, Spain

Andreu Soldevila Fabrega
LeanBio, Spain

Alastair Waugh
3P Biopharmaceuticals, Spain

Carles Celma Lezcano
Kymos Pharma Services, Spain

Tiziana Bonaldi
European Institute of Oncology, Italy

Maria De Angelis
University of Bari Aldo Moro, Italy

Jasmina N Jovanovic
School of Pharmacy, UK

Huseyin Cimen
Yeditepe University, Turkey

Stefanie Wienkoop
University of Vienna, Austria

PAST AFFILIATES

PAST AFFILIATES

Tamar Geiger
Tel Aviv University, Israel

David Sheehan
University Cork College, Ireland

Martine Cadene
Centre de Biophysique Moléculaire, France

Claudine S Bonder
University of South Australia, Australia

Fuad Fares
University of Haifa, Israel

Eunjoo Kim
Daegu Gyeongbuk Institue of Science and Technology (DGIST), South Korea

Jaime Jacqueline Jayapalan
University of Malaya, Malaysia

Serhiy Souchelnytskyi
Qatar University, Qatar

Vadim Govorun
Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Russia

Akira Imaizumi
Ajinomoto Co., Inc., Japan

Amilcar Perez-Riverol
Sao Paulo State University, Brazil

Mohamad Khairi Zainol
Universiti Malaysia Terengganu, Malaysia

Hasni Arsad
Universiti Sains Malaysia, Malaysia

Carlos Eduardo A Souza
Cisne University, Brazil

Diogo Ribeiro Demartini
Laboratorio de Proteinas Toxicas UNIPROTE-MS Centro de Biotecnologia – UFRGS , Brazil

Jamal Alruwaili
Vice Dean Faculty of Applied Medical Sciences Northern Border University Arar, Saudi Arabia

Nadeem A. Kizilbash
Northern Border University, Saudi Arabia

Chin Chiew Foan
University of Nottingham, Malaysia

Jianshe Zhang
Changsha University, China

John F Cipollo
Center for Biologics Evaluation and Research-USFDA, USA

Wendy Sandoval
Genentech, Inc. South San Francisco, USA

Xuequn Chen
School of Medicine, Wayne State University, USA

Alan J. Tackett
University of Arkansas for Medical Sciences, USA

Euro Biosimilars **Glimpses**





















London Attractions

